RUA Life Sciences is a holding company for a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-EonTM).
Fundraising completed
On 30th December 2020, RUA reported that shareholders had approved resolutions regarding the...
Read moreChristmas comes early – Fundraising and Interims
RUA have announced a Placing and Open Offer conditional on shareholder approval at a General...
Read moreHeart valve progress
RUA have announced an earlier than expected update on the testing of its Elast-Eon-coated...
Read more‘A fully formed medical device manufacturer’
RUA Life Sciences announced its trading update for the six months to 30 September 2020. The global...
Read more
Graft progress reflected in new valuation
RUA Life Sciences has announced that their graft products have moved into the final long-term...
Read moreCEO & Chairman Interview - Positive AGM statement
Chairman, Bill Brown and CEO, David Richmond discuss a year of substantial change and progress for...
Read morePositive AGM statement
RUA have provided a recent flurry of positive news, including an update on RUA Vascular division’s...
Read more‘The transformation continuum’
Following the acquisition of RUA Medical Devices Limited by AorTech International plc, the...
Read more
A run of good news
Since AorTech’s May trading update the company has continued its run of positive news announcements...
Read moreTrading update
In a reassuring and well-received trading update ahead of FY 2020 results set for July, Aortech...
Read more- Prev
- 1 of 2 pages
- Next
Register for updates
Sign up to get access to our latest content as soon as it’s published
